PittGene Meeting

Presenter: Bianca Seminotti, PhD | University Club at University of Pittsburgh, Pittsburgh, PA | Wednesday, October 25, 2023, 2:00-2:45pm ET

Mavodelpar Clinical Development Program in Adult Patients with Primary Mitochondrial Myopathies: Results from a Phase 1b Study and Design of Ongoing Pivotal Study (STRIDE)

Dr Rob Pitceathly – SSIEM conference presentation Weds 30th August, 2023, 9.30am

Reneo Pharmaceuticals Clinical Trial Update Presentation

Alejandro Dorenbaum, MD – UMDF June 30, 2023

Clinical Manifestations and Disease Burden of Primary Mitochondrial Myopathies (PMM): Results from a Patient Journey Analysis Shows Substantial Healthcare Resource Utilization

Sirimanne et al., UMDF 2023

Mavodelpar clinical development program in adult patients with primary mitochondrial myopathies (PMM): Design of the ongoing pivotal study (STRIDE) based on results from Phase 1b PMM study in adult patients

Pitceathly et al., Euromit 2023

An open-label study to evaluate the safety and tolerability of 12 weeks of treatment with oral REN001 in subjects with long-chain fatty acid oxidation disorders (LC-FAOD)

Vockley et al., INFORM 2022

A prospective, multicenter, non-interventional study to investigate the disease characteristics of adult patients with long-chain fatty acid oxidation disorders: The FORWARD study

Gillingham et al., INFORM 2022

REN001, a novel peroxisome proliferator-activated receptor delta (PPARδ)agonist, improves gait in patients with primary mitochondrial myopathy after 12-weeks

Alcock et al., Neuromuscular Medicine, 2022

Characterization of Fatigue in Primary Mitochondrial Myopathy: Findings from a Qualitative Interview Study

Karaa et al., UMDF Mitochondrial Medicine, 2021